Lixte Biotechnology Holdings, Inc.

NASDAQ:LIXT

Biotechnology

Healthcare
$7.21 +6.61%

+$0.46 today

Market cap
$89.11M
Beta
1.05
P/E (TTM)
-11.1
EPS (TTM)
-$0.67
52W Low $0.68High $7.78

Volume 0.61M

Average 0.12M

LIXT EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$0.18, compared with -$0.29 a year earlier. Trailing-twelve-month EPS (Basic) was -$1.13.

Context

  • EPS (Basic) grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly EPS (Basic) holds near -$0.18 or moves back toward the trailing-twelve-month quarterly average of -$0.28.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.18+45.5% QoQ
Last fiscal yearDec 2025
-$1.26+20.8% YoY
LTMMar 2026
-$1.13+22.1% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.9%——
1 year+20.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(1.26) USD
Year-over-year change
+20.8%

EPS (Basic) vs competitors

How LIXT compares with its peers on the latest reported figures

  • LIXT's LTM Mar 2026 EPS (Basic) of -$1.13 is the highest of the 2 companies compared; the peer median is -$5.02.
  • Its year-over-year change of +22.1% is the highest of 2, against a peer median of +12.8%.
LIXT Competitors Peer median
EPS (Basic) for LIXT and competitors
Company Period LTM YoY 3-year CAGR
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 2026-$1.13 +22.1%—
CINGCingulate Inc.LTM Mar 2026-$5.02 +12.8%—
Peer median (excluding LIXT) -$5.02+12.8%—

Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development1.74M1.35M898.1K726.23K254.92K
Selling, General & Admin4.98M4.96M4.19M2.85M4.85M
Operating Expenses6.72M6.31M5.09M3.57M5.11M
Depreciation & Amortization00000
EBITDA(6.72M)(6.3M)(5.07M)(3.57M)(6M)
EBITDA Margin—————
Operating Income(6.72M)(6.31M)(5.09M)(3.57M)(5.11M)
Operating Margin—————
Interest Income62611.2K17.49K7.05K7.39K
Interest Expense7.41K8.88K16.23K16.82K9.16K
Other Income / Expenses(7.95K)(1.05K)3.21K(13.18K)(901.9K)
Income Before Tax(6.73M)(6.31M)(5.09M)(3.59M)(6.01M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(6.73M)(6.31M)(5.09M)(3.59M)(6.01M)
Net Margin—————
EPS (Basic)(5.00)(4.00)(2.66)(1.59)(1.26)
EPS (Diluted)(5.00)(4.00)(2.66)(1.59)(1.26)
Weighted Avg Shares1.35M1.58M1.91M2.25M48.41M
Weighted Avg Shares (Diluted)1.35M1.58M1.92M2.25M48.41M

Lixte Biotechnology Holdings, Inc.

NASDAQ:LIXT

Intrinsic Alpha fair value

Locked

Current Price

$7.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.